In Brief: Genome Therapeutics
Executive Summary
Genome Therapeutics: Files registration statement for 2 mil. share secondary offering of common stock, the Waltham, Mass.-based gene discovery company announces Jan. 10. Oppenheimer & Co. is the underwriter and has an over- allotment option of 300,000 shares. Genome intends to use net proceeds to fund R&D, particularly to accelerate human gene discovery programs, and for general corporate purposes, including working capital...